685 related articles for article (PubMed ID: 31088535)
21. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
[TBL] [Abstract][Full Text] [Related]
22. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
23. A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
Chen Y; Zhao Y; Bajor DL; Wang Z; Selfridge JE
J Genet Genomics; 2020 Jul; 47(7):389-395. PubMed ID: 33004309
[TBL] [Abstract][Full Text] [Related]
24. Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State.
Daemen A; Liu B; Song K; Kwong M; Gao M; Hong R; Nannini M; Peterson D; Liederer BM; de la Cruz C; Sangaraju D; Jaochico A; Zhao X; Sandoval W; Hunsaker T; Firestein R; Latham S; Sampath D; Evangelista M; Hatzivassiliou G
Cell Metab; 2018 Sep; 28(3):383-399.e9. PubMed ID: 30043751
[TBL] [Abstract][Full Text] [Related]
25. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
[TBL] [Abstract][Full Text] [Related]
27. Glutamate enrichment as new diagnostic opportunity in breast cancer.
Budczies J; Pfitzner BM; Györffy B; Winzer KJ; Radke C; Dietel M; Fiehn O; Denkert C
Int J Cancer; 2015 Apr; 136(7):1619-28. PubMed ID: 25155347
[TBL] [Abstract][Full Text] [Related]
28. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism.
Budczies J; Brockmöller SF; Müller BM; Barupal DK; Richter-Ehrenstein C; Kleine-Tebbe A; Griffin JL; Orešič M; Dietel M; Denkert C; Fiehn O
J Proteomics; 2013 Dec; 94():279-88. PubMed ID: 24125731
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
30. Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes.
Tran TQ; Ishak Gabra MB; Lowman XH; Yang Y; Reid MA; Pan M; O'Connor TR; Kong M
PLoS Biol; 2017 Nov; 15(11):e2002810. PubMed ID: 29107960
[TBL] [Abstract][Full Text] [Related]
31. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.
Momcilovic M; Bailey ST; Lee JT; Fishbein MC; Magyar C; Braas D; Graeber T; Jackson NJ; Czernin J; Emberley E; Gross M; Janes J; Mackinnon A; Pan A; Rodriguez M; Works M; Zhang W; Parlati F; Demo S; Garon E; Krysan K; Walser TC; Dubinett SM; Sadeghi S; Christofk HR; Shackelford DB
Cell Rep; 2017 Jan; 18(3):601-610. PubMed ID: 28099841
[TBL] [Abstract][Full Text] [Related]
32. Glutaminase (GLS1) gene expression in primary breast cancer.
Vidula N; Yau C; Rugo HS
Breast Cancer; 2023 Nov; 30(6):1079-1084. PubMed ID: 37679553
[TBL] [Abstract][Full Text] [Related]
33. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.
Jin H; Wang S; Zaal EA; Wang C; Wu H; Bosma A; Jochems F; Isima N; Jin G; Lieftink C; Beijersbergen R; Berkers CR; Qin W; Bernards R
Elife; 2020 Oct; 9():. PubMed ID: 33016874
[TBL] [Abstract][Full Text] [Related]
34. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
35. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
Yu J; Qin B; Moyer AM; Sinnwell JP; Thompson KJ; Copland JA; Marlow LA; Miller JL; Yin P; Gao B; Minter-Dykhouse K; Tang X; McLaughlin SA; Moreno-Aspitia A; Schweitzer A; Lu Y; Hubbard J; Northfelt DW; Gray RJ; Hunt K; Conners AL; Suman VJ; Kalari KR; Ingle JN; Lou Z; Visscher DW; Weinshilboum R; Boughey JC; Goetz MP; Wang L
Breast Cancer Res; 2017 Dec; 19(1):130. PubMed ID: 29212525
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.
Rajeshkumar NV; Yabuuchi S; Pai SG; De Oliveira E; Kamphorst JJ; Rabinowitz JD; Tejero H; Al-Shahrour F; Hidalgo M; Maitra A; Dang CV
Clin Cancer Res; 2017 Sep; 23(18):5639-5647. PubMed ID: 28611197
[No Abstract] [Full Text] [Related]
37. Metabolic fingerprinting reveals extensive consequences of GLS hyperactivity.
Rumping L; Pras-Raves ML; Gerrits J; Tang YF; Willemsen MA; Houwen RHJ; van Haaften G; van Hasselt PM; Verhoeven-Duif NM; Jans JJM
Biochim Biophys Acta Gen Subj; 2020 Mar; 1864(3):129484. PubMed ID: 31734463
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
[TBL] [Abstract][Full Text] [Related]
40. Merging transcriptomics and metabolomics--advances in breast cancer profiling.
Borgan E; Sitter B; Lingjærde OC; Johnsen H; Lundgren S; Bathen TF; Sørlie T; Børresen-Dale AL; Gribbestad IS
BMC Cancer; 2010 Nov; 10():628. PubMed ID: 21080935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]